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Abstract
Background: Chemotherapy may improve survival in patients undergoing resection of colorectal liver
metastases (CLM). Neoadjuvant chemotherapy may help identify patients with occult extrahepatic disease
(averting unnecessary metastasectomy), and it provides in vivo chemosensitivity data.
Methods: A phase II trial was initiated in which patients with resectable CLM received CPT-11, 5-FU and
LV for 12 weeks. Metastasectomy was performed unless extrahepatic disease appeared. Postoperatively,
patients with stable or responsive disease received the same regimen for 12 weeks. Patients with
progressive disease received either second-line chemotherapy or best supportive care. The primary
endpoint was disease-free survival (DFS); secondary endpoints included overall survival (OS) and safety.
Results: 35 patients were accrued. During preoperative chemotherapy, 16 patients (46%) had grade 3/4
toxicities. Resection was not possible in 5 patients. One patient died of arrhythmia following surgery, and
1 patient had transient liver failure. During the postoperative treatment phase, 12 patients (55%) had grade
3/4 toxicities. Deep venous thrombosis (DVT) occurred in 11 patients (34%) at various times during
treatment. Of those who underwent resection, median DFS was 23.0 mo. and median OS has not been
reached. The overall survival from time of diagnosis of liver metastases was 51.6 mo for the entire cohort.
Conclusion: A short course of chemotherapy prior to hepatic metastasectomy may serve to select
candidates best suited for resection and it may also direct postoperative systemic treatment. Given the
significant incidence of DVT, alternative systemic neoadjuvant regimens should be investigated, particularly
those that avoid the use of a central venous line.
Trial Registration: ClinicalTrials.gov NCT00168155.
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Background
The liver is the most common site of metastasis for color-
ectal cancer. Resection is the only hope for long-term sur-
vival for CLM. The median survival in such patients prior
to recent advances in chemotherapy ranged from 19 – 30
mo, with five year survivals of 30–39% [1-3]. Recent stud-
ies have reported even better survivals [1,2,4,5]. This may
be due to improved chemotherapy, administered during
various times of the patient's illness. Typically, response
rates for first line chemotherapy are 39–60% [6-9]. While
improvements in survival have been reported in unresect-
able metastatic colorectal cancer, there is little evidence on
how best to administer these agents in the setting of
resectable CLM.
We have recently published a detailed description of a
phase II clinical trial involving the perioperative adminis-
tration of CPT-11, 5-FU and LV to patients with resectable
CLM [10]. Neoadjuvant chemotherapy has a number of
potential advantages in this setting. First, the degree of
response provides information on the in vivo chemosensi-
tivity of tumors. This may help to determine the appropri-
ateness of administering the same chemotherapy after
resection. In non-responders, the toxicities of these agents
are avoided and alternatives can be considered. Adminis-
tration of preoperative chemotherapy may also enable
selection of candidates for resection. In particular,
patients who develop extrahepatic disease during a short
course of chemotherapy were likely unsuitable candidates
for resection in the first place. Finally, in some instances,
neoadjuvant chemotherapy may enhance resectability, as
reductions in tumor volume may limit the amount of the
liver that will need to be removed to eradicate all gross dis-
ease [11]. We herein report our experience with this
approach. Importantly, we describe our results in an
intent-to-treat fashion.
Methods
The trial was registered with ClinicalTrials.gov (registra-
tion #NCT00168155). The trial was approved by the Con-
joint Health Research Ethics Board at the University of
Calgary, as well as by the local Ethics committees of col-
laborating participating institutions. Informed, written
consent was obtained from all patients. A detailed
description of the protocol was recently reported [10]. In
brief, the general aim was to determine the efficacy of neo-
adjuvant chemotherapy for patients with resectable CLM
in reducing recurrence rate. The primary objective was to
evaluate disease-free survival. Secondary objectives
included documentation of safety and evaluation of over-
all survival.
Inclusion and Exclusion Criteria
Inclusion criteria included the following: (a) patients with
Stage IV colorectal adenocarcinoma isolated to the liver;
(b) at least one radiographically measurable lesion; (c)
determination by a hepatobiliary surgeon that the liver
metastases were amenable to complete resection and/or
radiofrequency ablation (RFA). Exclusion criteria
included the following: (a) the primary tumor was not
controlled by locoregional treatments; and (b) previous
chemotherapy for metastatic colorectal cancer.
A biopsy was initially required. However, in the latter
stages of the trial, enrollment was also permitted in
patients with all of the following criteria: liver lesions with
typical features of CLM on MRI and CT; FDG uptake on
PET imaging; and elevated serum CEA. These latter criteria
only applied to two patients.
Treatments
Chemotherapy was administered for 12 weeks in the pre-
operative period. At 6 – 8 weeks, the clinical response was
assessed by abdominal CT. If progression was not identi-
fied, the remaining cycles of chemotherapy were given.
The first two patients received chemotherapy as described
by Saltz et al. [6]. Chemotherapy was administered as per
Douillard and colleagues [7] in 30 patients, and the
remaining patients received chemotherapy as per the
FOLFIRI regimen [12]. The reason for changes in regimen
were related to changes in standards of practice for pallia-
tive treatment of metastatic colorectal cancer during the
trial. The method of vascular access for administration of
chemotherapy was at the discretion of the medical oncol-
ogist.
The extent of hepatic resection was determined by the sur-
geon. A resection margin of at least 1 cm was the goal. In
patients where one or more of the CLM was not felt to be
resectable for either technical or patient-related reasons,
RFA was performed with the goal of a 1 cm ablation mar-
gin. All RFAs were done in an open fashion.
All patients with stable and responsive disease following
preoperative chemotherapy who had undergone liver
resection were offered 12 additional cycles of the same
chemotherapy. The goal was to initiate adjuvant chemo-
therapy 21 – 72 days after surgery. Patients with progres-
sive disease were offered an alternative agent or best
supportive care.
Prophylactic anticoagulants were not administered rou-
tinely during chemotherapy. Standard antithrombotic
prophylaxis prior to surgery consisted of administration
of subcutaneous heparin and application of intermittent
compression stockings.
Data Analysis
A detailed analysis plan and definitions related to out-
comes were previously published [10]. Response to chem-BMC Cancer 2009, 9:156 http://www.biomedcentral.com/1471-2407/9/156
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otherapy was determined by RECIST criteria [13]. Date of
diagnosis was considered the date of biopsy-proven CLM,
except in the case of synchronous CLM (in which case the
date of diagnosis was considered the date of surgery for
the primary tumor) or in cases where diagnosis was clini-
cal (in which case the date of the final qualifying diagnos-
tic test was considered the date of diagnosis).
It was estimated that 70 patients would be required to
demonstrate an improvement in 2-year disease-free sur-
vival of 25%, given an estimated historical 3 year disease-
free survival of 40% (i.e, P0), with an alpha 0.05 and a
power of 0.8, by 2-tailed test. The study was stopped pre-
maturely due to safety concerns as outlined below.
Survival was estimated by the method of Kaplan-Meier.
The log-rank test was used to test for differences in survival
times. A p-value of < 0.05 was considered significant. All
analyses were made on an intent-to-treat basis, since that
would provide the most meaningful information for a
cohort of patients considered upfront to have resectable
disease.
Adverse events related to chemotherapy were graded
according to CTCAE Version 3.0 http://ctep.info.nih.gov.
Adverse events were attributed to the chemotherapy if
they occurred within 30 days of the last dose. Operative
mortality was defined as death within 30 days of opera-
tion or during the same hospitalization.
Results
Patients
From December, 2001 – July, 2005, 35 patients were
accrued. The characteristics of this cohort are summarized
in Table 1. Synchronous CLM were defined as the discov-
ery of CLM ≤ 2 months after diagnosis of colorectal can-
cer. Of those with metachronous tumors (40%), the
median disease-free interval was 24 mo (range 4 – 61);
adjuvant chemotherapy had been administered prior to
accrual in 11 of those patients. The average number of
CLM was 2 ± 3 (range: 1 – 20). The largest lesions meas-
ured 5.0 ± 2.6 cm (range: 1.4 – 13.7 cm).
Treatment Pathways
Treatments administered to the study cohort are summa-
rized in Figure 1. Two patients stopped their preoperative
chemotherapy before their response was evaluated (one
due to refusal related to anxiety from the delay of surgery;
the other because of the appearance of a DVT, which
prompted that individual to decline further chemother-
apy). A response to chemotherapy was seen in 14 patients
(40%; 1 CR and 13 PR); 12 patients (36%) had stable dis-
ease; and 7 patients (18%) had progression. All radio-
graphic responses were confirmed pathologically. Two of
the patients with progressive disease were identified dur-
ing the mid-interval CT; increased tumor size but no new
metastases were observed. Surgery was ultimately per-
formed on 31 patients, of whom 30 (97%) underwent
successful R0 resection or ablation. One patient was
found at laparotomy to have extrahepatic disease.
Laparotomy was not performed in 4 patients, due to the
appearance of extrahepatic disease (N = 2), clinical deteri-
oration (N = 1), or refusal (N = 1). Twenty-two patients
received postoperative chemotherapy. These comprised
patients with measurable responses or stable disease. Four
patients with stable disease did not receive postoperative
chemotherapy because of refusal (N = 2); poor postoper-
ative recovery (N = 1); or surgical death (N = 1). Patients
with progression who underwent resection did not receive
postoperative chemotherapy. Patients who progressed to
nonresectability were all given second-line chemotherapy
(FOLFOX).
Average time from last dose of preoperative chemother-
apy to surgery was 50 ± 34 d. Average time from the date
of surgery to the initiation of postoperative chemotherapy
was 58 ± 11 d.
Treatment-related Toxicities
The toxicities related to preoperative chemotherapy are
outlined in Table 2. Seven patients (20%) did not receive
all scheduled courses of chemotherapy and two of those
Table 1: Patient characteristics at time of accrual.
Parameter
Total Number of Patients 35
Age 59 ± 8 years
Gender
Male 24 (69%)
Female 11 (31%)
Site of Primary Tumor
Colon 22 (63%)
Rectosigmoid 7 (20%)
Rectum 6 (17%)
Previous Treatment for Primary Tumor
Chemotherapy 11 (31%)
Radiotherapy 6 (17%)
Initial Staging
Stage I 1 (3%)
Stage II 4 (11%)
Stage III 9 (26%)
Stage IV (ie: synchronous liver metastases) 21 (60%)
Metachronous liver metastases 14 (40%)
Median disease-free interval (range) 24 mo (4–61 mo)
Mean Number of Liver Lesions 2 ± 3
Solitary metastasis 21 (60%)
> 1 metastases 14 (40%)
Size of Largest Liver Lesion 5.0 ± 2.6 cm
≤ 5 cm 21 (60%)
> 5 cm 14 (40%)
Carcinoembryogenic Antigen 31 ± 41 ng/mLBMC Cancer 2009, 9:156 http://www.biomedcentral.com/1471-2407/9/156
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were because of disease progression seen on interval CT.
Severe adverse events occurred in 6 patients (14%),
including DVT/PE (N = 1), myocardial infarction (N = 1),
pseudomembranous colitis (N = 1), pneumonia (N = 1),
small bowel perforation (N = 1), and hypokalemia (N =
1).
Surgical outcomes are summarized in Table 3. Median
blood loss was 500 mL (range 100 – 3000). Median
length of stay was 9 d (range 5 – 24 d). Major complica-
tions occurred in 6 patients (17%), including delirium (N
= 2), liver failure (N = 1), myocardial infarction (N = 1),
intraabdominal abscess (N = 1), peripheral neuropathy
(N = 1) and death due to an arrhythmia of unknown eti-
ology (N = 1). Thus, operative mortality of liver resection
was 3%. The autopsy of the patient who died on the sec-
ond postoperative day revealed no evidence of throm-
boembolic (TE) complications or myocardial infarction,
but the liver was affected by severe steatohepatitis.
Distribution of patients who received each phase of treatment Figure 1
Distribution of patients who received each phase of treatment.BMC Cancer 2009, 9:156 http://www.biomedcentral.com/1471-2407/9/156
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Table 2: Adverse events based on worst grade toxicity experienced during preoperative and postoperative chemotherapy.
Adverse Event Preoperative Chemotherapy (n = 35) Postoperative Chemotherapy (n = 22)
Grade 1/2
N (%)
Grade 3/4
N (%)
Grade
1/2
N (%)
Grade 3/4
N (%)
Gastrointestinal
Nausea/vomiting 25 [71] 0 (0) 17 (77) 0 (0)
Diarrhea 19 (54) 2 (6) 11 (50) 1 (5)
Constipation 8 (23) 1 (3) 8 (36) 0 (0)
Anorexia 7 (20) 0 (0) 3 (14) 0 (0)
Mucositis/stomatitis 11 (31) 0 (0) 8 (36) 0 (0)
Small Bowel Perforation 0 (0) 1 (3) 0 (0) 0 (0)
Other: heartburn, dyspepsia, gas pain, taste 
alteration, dysgeusia, hiccups, dry mouth, abdominal 
cramping, dysphagia
12 (34) 0 (0) 11 (50) 0 (0)
Constitutional
Fatigue or lethargy or insomnia 30 (86) 0 (0) 16 (73) 0 (0)
Diaphoresis/flushing 4 (11) 0 (0) 1 (5) 0 (0)
Other: fever, cough, cold 3 (9) 0 (0) 1 (5) 0 (0)
Infection 10 (29) 2 (6) 5 (23) 2 (9)
Pain 7 (20) 0 (0) 7 (32) 0 (0)
Laboratory: Hematological
Lymphopenia 1 (3) 2 (6) 2 (9) 0 (0)
Neutropenia 12 (34) 4 (11) 8 (36) 9 (41)
Anemia 13 (37) 0 (0) 9 (41) 0 (0)
Thrombocytopenia 4 (11) 0 (0) 8 (36) 0 (0)
Laboratory: Biochemistry
Elevated liver function tests: AST, ALT, bilirubin, 
alkaline phosphatase, LDH
6 (17) 0 (0) 5 (23) 0 (0)
Elevated creatinine 2 (6) 0 (0) 1 (5) 0 (0)
Decreased protein/albumin 2 (6) 0 (0) 2 (9) 0 (0)
Coagulation abnormalities: INR/PTT 0 (0) 1 (3) 0 (0) 1 (5)
Miscellaneous electrolyte and metabolic 
disturbances: hypermagnesemia, elevated 
phosphorous, hypocalcemia, hypokalemia
2 (6) 1 (3) 1 (5) 0 (0)
Thromboembolic
Deep vein thrombosis 0 (0) 5 (14) 0 (0) 4 (18)
Acute myocardial infarction 0 (0) 1 (3) 0 (0) 0 (0)
Dermatology/Skin
Erythemia, rash, desquamation 7 (20) 0 (0) 5 (23) 0 (0)
Alopecia 7 (20) 0 (0) 4 (18) 0 (0)
Miscellaneous: Other
Blurred vision/eye irritation 6 (17) 0 (0) 4 (18) 0 (0)
Mood alteration: agitation, anxiety, depression, 
hyperactivity
7 (20) 2 (6) 5 (23) 0 (0)BMC Cancer 2009, 9:156 http://www.biomedcentral.com/1471-2407/9/156
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Hepatic steatosis was identified in 20 of the 30 pathology
reports from surgical specimens (67%).
The toxicities related to postoperative chemotherapy are
summarized in Table 2. Of the 22 patients who received
postoperative chemotherapy, 7 patients (32%) did not
have all courses, although 21 patients (96%) had more
than 50% of scheduled cycles. Severe adverse events
occurred in 5 patients (23%), including DVT (N = 3),
severe diarrhea (N = 1) and vomiting (N = 1).
The trial was discontinued early because of a high inci-
dence of TE complications (N = 11; 36%). During preop-
erative chemotherapy, 6 patients had such complications
(including 1 patient with lower extremity DVT and a pul-
monary embolus, 4 patients with DVT at the central line
(CVL), and 1 patient with myocardial infarction). Two
patients were noted perioperatively to have DVTs at the
site of the CVL. Three patients had TE complications that
first appeared during postoperative chemotherapy, and all
of these patients had DVTs at the site of the CVL. In one
patient with an upper extremity DVT during preoperative
chemotherapy, clot propagation occurred despite being
on low molecular weight heparin. While DVT/PE was not
considered a priori in the stopping rules for the clinical
trial, the high incidence and the attendant risks of using
anticoagulants at the time of liver surgery was sufficiently
compelling to discontinue the trial.
Survival
Median follow-up for all patients was 38.8 mo. For
patients who underwent resection, the median DFS (time
of liver resection to time of recurrence) was 23.0 mo (Fig-
ure 2A) and 2-year DFS was 47%. Recurrences typically
occurred in the liver (N = 2), the lungs (N=4), or both (N
= 4). Other sites of recurrence included anastomotic recur-
rence (N = 2); retroperitoneal lymph nodes (N = 1) and
abdominal wall (N = 3). Median disease-free survival was
21.2 and 20.3 mo for patients with a response and
patients with stable disease, respectively. Only two
patients with progressive disease underwent resection.
They recurred at 5.8 and 18.8 mo (median DFS 12.3 mo).
The differences between response groups were not statisti-
cally significant.
Median OS for patients who underwent resection has not
been reached (Figure 2B). Two-year OS for patients who
underwent resection was 93%. The two patients with pro-
gressive disease who underwent resection survived for
43.5 and 39.0 months without another resection.
The median OS from the time of diagnosis of CLM (for all
patients enrolled in the trial) was 51.6 mo (Figure 3A). If
measured from the time of initiation of chemotherapy,
median OS for the entire cohort was 51.0 months. At 2
years, OS for the whole cohort was 86%. Overall survival
was found to be a function of chemosensitivity. Median
OS for those who had a response to chemotherapy and
those who had stable disease has not been reached;
median OS for those with progressive disease was 37.1 mo
from time of diagnosis (and 32.2 mo from the start of
chemotherapy). Using an intent-to-treat analysis (which
accounts for outcomes related to all patients, including
Table 3: Surgical outcomes.
Surgical Procedures
Number of laparotomies 31 (89%)
Number of liver resections 30 (86%)
Number radiofrequency ablations 4 (11%)
Estimated blood loss (mL) 728 ± 619
Days in hospital 9.6 ± 4.0
Major complications 6 (19.4%)
Mortalities 1 (3%)
Kaplan-Meier curves illustrating disease-free survival (A) and  overall survival (B) from time of diagnosis, in patients who  underwent liver resection Figure 2
Kaplan-Meier curves illustrating disease-free survival 
(A) and overall survival (B) from time of diagnosis, in 
patients who underwent liver resection.BMC Cancer 2009, 9:156 http://www.biomedcentral.com/1471-2407/9/156
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those who did not undergo resection), the relationship
between OS and response to chemotherapy was signifi-
cant (P = 0.003; Figure 3B).
Discussion
Until recently, most reports on preoperative chemother-
apy for CLM focused its utility in the context of unresect-
able CLM [14-17]. Unresectable CLM can be converted to
a resectable state in 3.3 – 32.5% of patients. [12,15,17-
19]. In this trial, we have administered preoperative
chemotherapy for resectable disease. While the strength of
any conclusions on the survival benefits of chemotherapy
were diminished by the early cessation of the trial as well
as the general design of the trial, it did appear that admin-
istration of preoperative CPT-11, 5-FU and LV has utility
in selecting patients for surgery and postoperative chemo-
therapy. However, a number of caveats to this strategy
were identified. In particular, there may have been prob-
lems related to impaired liver function and there was a
high incidence of thromboembolic events.
We have observed a favorable OS (based on an intent-to-
treat analysis) of 51.6 months, and 5 liver resections (4
laparotomies) were avoided. Of patients who underwent
liver resection, 2-year DFS was 47%. Other reports on the
use of chemotherapy for resectable CLM put our results
into context. In a series of patients who were selected to
receive preoperative FOLFOX and postoperative FOLFIRI
or postoperative FOLFOX and FOLFIRI, median time to
recurrence was 17 mo, but no long-term outcomes related
to preoperative chemotherapy were reported [20]. Resec-
tion followed by adjuvant 5-FU and LV was seen to
improve DFS over surgery alone in two studies [4,21]. In
these trials, OS for patients given postoperative chemo-
therapy was 47 mo and 62.1 mo, respectively. Thus, we
have realized good long-term outcomes in our series
despite our intent-to-treat analysis, which takes into
account patients who did not undergo resection.
Disease progression was anticipated to be the most con-
cerning adverse outcome. We considered that, if intrahe-
patic disease progressed to a point where resection was no
longer an option, then the preoperative chemotherapy
had not served the patient well. This did not occur in any
of our patients. In contrast, if an extrahepatic focus of dis-
ease appeared while on chemotherapy, then the interval
of observation was useful in averting an unnecessary liver
resection. This occurred in 3 of our patients (8.6%). Other
studies have also demonstrated that neoadjuvant chemo-
therapy has little impact on technical resectability [22-24].
Most of the liver resections that were avoided were well
justified. In addition, only one patient had a laparotomy
without resection. This compares favorably to the series
reported by Wein et al., who could achieve successful
resections in 80% of patients with primarily resectable
liver metastases following a course of oxaliplatin-based
chemotherapy [25]. This difference may be because, in the
latter study, preoperative chemotherapy was administered
for much longer (16 – 24 weeks).
The favorable survival seen in those who underwent resec-
tion suggests that preoperative chemotherapy provided a
means of selecting better candidates for resection. Others
have also suggested that preoperative chemotherapy has a
selective influence [23,26,27]. In one large retrospective
series [26], patients who progressed on preoperative
chemotherapy fared poorly after liver resection, with 5-
year OS and DFS of only 8% and 3%, respectively. When
such a strategy was utilized for patients not judged to have
optimally resectable disease, resection was possible in
A Kaplan-Meier curve illustrating overall survival in all  patients enrolled in the study Figure 3
A Kaplan-Meier curve illustrating overall survival in 
all patients enrolled in the study. B. Overall survivals 
of all patients enrolled in the study as a function of 
response to chemotherapy.BMC Cancer 2009, 9:156 http://www.biomedcentral.com/1471-2407/9/156
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40% of patients and the authors argued that the lack of
response in the remaining was prognostic [27]. The
recently reported EORTC trial demonstrated in a rand-
omized controlled fashion an improvement in survival in
patients treated with perioperative FOLFOX versus surgery
alone [24]. Perioperative chemotherapy was associated
with an 8.1% improvement in progression-free survival at
3 years. However, no data were presented that suggested a
role for preoperative chemotherapy in the selection of
resection candidates. The question remains whether all
patients with resectable CLM should receive such a regi-
men. Until trials comparing neoadjuvant and adjuvant
chemotherapy for resectable CLM are done, it may be pru-
dent to administer such a strategy in patients with higher
risk of recurrence, such as those with numerous or large
CLM; synchronous CLM or short disease-free interval;
high serum CEA; equivocal lung lesions on CT scan; or a
low likelihood of achieving negative margins [3,5].
Preoperative chemotherapy is not without risk. One
potential risk is postoperative liver dysfunction, as chem-
otherapy is associated with alterations in the hepatic
parenchyma such as sinusoidal dilatation, steatosis, and
steatohepatitis [28-30]. Steatosis is associated with
increased surgical morbidity [30]. Preoperative FOLFOX
is associated with a higher risk of postoperative hyperbi-
lirubinemia [24]. Irinotecan-containing regimens are
associated with steatohepatitis, and patients with this
lesion have an increased surgical mortality [29]. Indeed,
we observed that 67% of individuals on this chemother-
apy regimen had steatosis in their pathological specimen.
One patient had postoperative liver failure. It is possible
that the arrhythmic death observed was secondary to
impaired hepatic metabolism of drugs. We believe that
administration of preoperative chemotherapy (especially
those regimens containing irinotecan) is associated with a
risk of hepatic dysfunction that might alter outcomes. If
neoadjuvant chemotherapy is more widely utilized in the
future, some consideration to methods of averting hepa-
totoxicity should be made.
One risk that was not fully appreciated was the risk of TE
complications. Patients had a high baseline risk due to the
presence of malignancy and because major surgery was
performed. The insertion of indwelling CVLs was an addi-
tional risk factor [31]. Significant TE events have previ-
ously been reported with CPT-11 and bolus 5-FU/LV
[32,33], although such a regimen was only administered
to two patients in our study. It is possible that the drug
combination itself may be thrombogenic, particularly in
the context of surgical patients. The incidence of TE events
in our study was higher than anticipated, even compared
to another study in which a similar chemotherapy regi-
men was utilized prior to liver resection [15]. The impact
of a TE event during preoperative chemotherapy is consid-
erable, as it necessitates perioperative administration of
anticoagulants to patients undergoing surgery associated
with a high risk of bleeding. We believe that the high inci-
dence of TE complications could partly be averted by the
use of an oral fluoropyrimidine, which would avoid the
use of a CVL.
Our experience demonstrates that administration of peri-
operative chemotherapy is feasible in a setting where
patient care can be coordinated through a close collabora-
tion between surgical and medical disciplines. We have
demonstrated that the strategy as a whole is associated
with good long-term outcomes, even when analyzed in an
intent-to-treat fashion. While any conclusions related to
survival outcomes have been significantly weakened by
the premature cessation of the trial, there is evidence from
this trial and from others [23,26,27] that the strategy may
be beneficial in selecting the most appropriate patients for
resection. Patients who experience clinical deterioration
on chemotherapy or who develop extrahepatic disease are
removed from the pool of resection candidates. It may
also be argued that resection should not be performed at
all in patients with progressive disease due to their poor
prognosis even with resection. On the other hand, pro-
gression in the face of resectable disease may simply spur
the use of alternative postoperative systemic treatments,
such as bevacizumab or cetuximab. Our data also demon-
strate that there are also significant risks to this approach
using combined irinotecan, 5-FU and LV. Our findings of
a high risk of thromboembolic complications and the
association with liver failure have led us to avoid the use
of irinotecan preoperatively, particularly over prolonged
durations. Future developments should include the avoid-
ance of drugs associated with an increased risk of TE
events and use of regimens in which a long-term intrave-
nous access is not necessary. Ultimately, it will be essential
to prospectively compare the relative merits of periopera-
tive chemotherapy and postoperative chemotherapy in
patients with resectable CLM.
Conclusion
A short course of chemotherapy prior to hepatic metasta-
sectomy may serve to select candidates best suited for
resection and it may also direct postoperative systemic
treatment. Given the significant incidence of DVT, alterna-
tive systemic neoadjuvant regimens should be investi-
gated, particularly those that avoid the use of a central
venous line.
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